Health Management Center, PLA 180 Hospital, Quanzhou, Fujian, China.
Department of Disease Prevention and Control, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujian, China.
Cancer Biomark. 2018;22(2):237-247. doi: 10.3233/CBM-170846.
People with biomarkers above cut-off values normally have higher risk to develop pre-malignancies and malignancies.
Here we investigate if serological TK1 protein (STK1p), AFP, CEA and PSA below cut-off values predict development of pre-cancer.
The mean values and the concentration distribution of STK1p, AFP, CEA and PSA were determined in a cohort of 56,178 persons participating a health screening group, consist of people with non-tumor diseases, pre-malignancy and diseases associated with the risk process of malignancy. A health disease-free group (n= 428) was selected among the 56,178 participants and used as controls.
The STK1p below cut-off value (⩽ 2 pM) showed partly (51.6%) an almost normal concentration distribution and partly (43.9%) an extensive tail in the health screening group, which was not found in the disease-free group. Due to the extensive tail in the distribution, the mean value of STK1p increased significantly (p= 0.0001) from 0.38 ± 0.30 pM in the health disease-free group to 0.69 ± 0.55 pM in the group below the cut-off value. No significantly differences in the concentration distribution and the mean values among gender and ages were observed. On the other hand, there were no difference in the concentration distributions and the mean values of AFP, CEA and PSA between the health disease - free group and the group below cut-off values, as well as between gender and ages. Of interest, the elevated mean value of STK1p of the group below the cut-off value was correlated to pre-malignancy and diseases associated with the risk process of malignancy in liver and prostate. No such correlations were found with AFP, CEA and PSA.
STK1p is a potential proliferating biomarker for early discover of persons in the risk to develop or already have pre-malignancies or diseases associated with the risk process of malignancy.
生物标志物高于临界值的人通常有更高的风险发展为前恶性肿瘤和恶性肿瘤。
在这里，我们研究血清 TK1 蛋白（STK1p）、AFP、CEA 和 PSA 低于临界值是否能预测癌前病变的发生。
在一个由 56178 名非肿瘤性疾病、前恶性肿瘤和与恶性肿瘤风险过程相关疾病患者组成的健康筛查组中，测定了 STK1p、AFP、CEA 和 PSA 的平均值和浓度分布。在 56178 名参与者中选择了一个健康无疾病组（n=428）作为对照组。
STK1p 低于临界值（⩽2pM）在健康筛查组中部分（51.6%）表现出几乎正常的浓度分布，部分（43.9%）表现出广泛的长尾分布，而在无疾病组中则没有发现。由于分布中的长尾，STK1p 的平均值显著增加（p=0.0001），从健康无疾病组的 0.38±0.30pM 增加到低于临界值组的 0.69±0.55pM。在性别和年龄方面，未观察到浓度分布和平均值的显著差异。另一方面，在健康无疾病组和低于临界值组之间，以及在性别和年龄方面，AFP、CEA 和 PSA 的浓度分布和平均值没有差异。有趣的是，低于临界值组的 STK1p 平均值升高与肝脏和前列腺的前恶性肿瘤和与恶性肿瘤风险过程相关的疾病相关。而 AFP、CEA 和 PSA 则没有发现这样的相关性。
STK1p 是一种潜在的增殖生物标志物，可用于早期发现有发展为前恶性肿瘤或已患有前恶性肿瘤或与恶性肿瘤风险过程相关疾病风险的人群。
